Proprietary Antibody Platform

Our world class, proprietary monoclonal antibody (mAb) discovery platform is a core strength upon which we continue to build and improve. Leveraging this platform, we are able to identify rare and broad antibodies with enhanced selectivity and potency using artificial intelligence-led (AI) protein engineering.

The platform has already yielded two commercial medicines, sotrovimab for COVID-19, which was developed in just 15 months and ansuvimab-zykl for Ebola, which has been recognized by the World Health Organization for its impact.

Our antibody discovery platform gives us a higher potential success rate in developing potential therapies with speed. It enables the identification of mAbs with unique features and further optimizes them through protein engineering to increase potency, breadth and immune engagement, including effector function and more.

Our iterative process allows us to holistically optimize multiple mAb properties and greatly reduce the time to clinic. Our AI engine dAIsY uses a mix of open source and proprietary tools that run in parallel, allowing us to fine tune multiple desirable mAb characteristics simultaneously, ultimately generating a lead mAb with high potential and accelerating the process by months.

In addition, using AI and lean thinking, we can also reduce the idea-to-IND time. We use an iterative proprietary process that allows us to holistically optimize multiple mAb properties using a mix of open source and proprietary tools that run in parallel to fine tune multiple desirable mAb characteristics at the same time to generate a lead mAb with the highest potential for commercial success.

To learn more about diseases we are targeting using our mAb technology, click here.